Fortrea Holdings (FTRE) Interest Coverage Ratio (2022 - 2023)
Fortrea Holdings (FTRE) reported Interest Coverage Ratio of 0.7 for Q4 2023, down 100.97% on a YoY basis from 71.5 in Q4 2022, and down 333.69% quarter-over-quarter from 0.3 in Q3 2023.
Fortrea Holdings (FTRE) Interest Coverage Ratio (2022 - 2023) Analysis & Trends
Fortrea Holdings has reported Interest Coverage Ratio for 2 years, with the latest figure at 0.7 in Q4 2023.
- For the quarter ending Q4 2023, Interest Coverage Ratio fell 100.97% year-over-year to 0.7; the trailing twelve-month figure through Sep 2024 stood at 3.78 (down 290.72% YoY), and the FY2023 full-year result was 0.46, down 99.95% from the prior year.
- Interest Coverage Ratio for Q4 2023 stood at 0.7, down from 0.3 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 71.5 in Q4 2022, with the low at 0.7 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.70 |
| Sep 30, 2023 | 0.30 |
| Jun 30, 2023 | 45.14 |
| Dec 31, 2022 | 71.50 |